National Cancer Institute National Cancer Institute
U.S. National Institutes of Health National Cancer Institute
NCI Home Cancer Topics Clinical Trials Cancer Statistics Research & Funding News About NCI
Gestational Trophoblastic Tumors Treatment (PDQ®)
Patient VersionHealth Professional VersionEn españolLast Modified: 12/05/2007



Purpose of This PDQ Summary







General Information






Cellular Classification






Stage Information






Treatment Option Overview






Hydatidiform Mole






Placental-Site Gestational Trophoblastic Tumors






Nonmetastatic Gestational Trophoblastic Tumors






Good-Prognosis Metastatic Gestational Trophoblastic Tumors






Poor-Prognosis Metastatic Gestational Trophoblastic Tumors






Recurrent Gestational Trophoblastic Tumors






Get More Information From NCI






Changes to This Summary (12/05/2007)






More Information



Page Options
Print This Page  Print This Page
Print This Document  Print Entire Document
View Entire Document  View Entire Document
E-Mail This Document  E-Mail This Document
Quick Links
Director's Corner

Dictionary of Cancer Terms

NCI Drug Dictionary

Funding Opportunities

NCI Publications

Advisory Boards and Groups

Science Serving People

Español
NCI Highlights
Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E

New Study of Targeted Therapies for Breast Cancer

The Nation's Investment in Cancer Research FY 2009

Cancer Trends Progress Report: 2007 Update

Past Highlights
You CAN Quit Smoking Now!
General Information

Gestational trophoblastic tumors (GTTs) are rare but highly curable tumors arising from the products of conception in the uterus. The prognosis for cure of patients with GTTs is good even when the disease has spread to distant organs, especially when only the lungs are involved. The probability of cure depends on the following:

  • Histologic type (mole, invasive mole, or choriocarcinoma).
  • Extent of spread of the disease.
  • Level of the human chorionic gonadotropin (hCG) titer.
  • Duration of disease from the initial pregnancy event to start of treatment.
  • Specific sites of metastases.
  • Nature of antecedent pregnancy.
  • Extent of prior treatment.

Selection of treatment depends on these factors plus the patient’s desire for future pregnancies. The hCG, produced normally during pregnancy, is abnormally elevated in the blood and urine of patients with this group of diseases and is a sensitive marker to indicate the presence or absence of disease before, during, and after treatment.

The most common antecedent pregnancy is that of a hydatidiform mole, usually a genetic disorder of pregnancy in which only placental-like tissue is present. The patient will present with abnormal bleeding from onset of pregnancy and may have a uterus which is much larger than expected. Sonography is the preferred method of diagnosis, and suction dilation and curettage (D & C) is the preferred method of evacuation. Of utmost importance is careful follow-up with serum beta hCG (BhCG) weekly until less than 100 mIU/mL and then every 2 weeks. The patient should have a careful pelvic examination every other week and a chest x-ray every 4to 6 weeks. Once the titer of serum BhCG has fallen to normal levels, these two examinations need no longer be done; however, BhCG titers need to be repeated every 2 weeks for 3 months, then monthly for 3 months, then every 2 months for 6 months, then every 6 months for 3 years. Each patient should be counseled in the use of a reliable birth control method. Any patient who develops an increasing level of serum BhCG, a plateau of the BhCG over 3 weeks, or persistent elevation of BhCG after 16 weeks of follow-up should be considered as having gestational trophoblastic neoplasia and should undergo the appropriate work-up and treatment. Similarly, any patient who develops metastatic disease during follow-up should be staged and undergo treatment.

Choriocarcinoma most commonly follows a molar pregnancy but can follow a normal pregnancy, ectopic pregnancy, or abortion, and should always be considered when a patient has continued vaginal bleeding in the postdelivery period. Other common signs include bizarre neurologic symptoms in a female within the reproductive age group and asymptomatic lesions on routine chest x-ray.

Back to TopBack to Top

< Previous Section  |  Next Section >


A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov